Talin-1 and Non-invasive Fibrosis Models in the Assessment of Patients with Hepatocellular Carcinoma

  • Alsebaey, Ayman (Hepatology department, National Liver Institute, Menoufia University) ;
  • Ahmedy, Iman Aly (Clinical Pathology Department, Faculty of Medicine, Menoufia University)
  • Published : 2016.08.01


Background: Hepatocellular carcinoma (HCC) is a dreadful complication of end stage liver disease with high morbidity and mortality. Aim: The aim was to assess the role of serum talin-1 and non-invasive fibrosis in patients with HCC. Materials and Methods: A total of eighty seven subjects were enrolled, with 22 two healthy individuals as a control group (n=22), 22 patients in the cirrhosis group and finally 43 in the group with HCC diagnosed with positive triphasic CT abdomen criteria. Serum talin-1 and noninvasive fibrosis parameters were assessed in all subjects. Results: Compared to the cirrhosis group, patients with HCC had higher serum talin-1 ($32.9{\pm}12.6$ vs. $11.1{\pm}2.79ng/ml$), FIB4 ($9.96{\pm}15.3$ vs. $2.90{\pm}1.87$) and $fibro-{\alpha}$ ($10.9{\pm}18.1$ vs. $1.55{\pm}0.28$) but not fibrosis index scores ($4.47{\pm}0.95$ vs. $4.98{\pm}0.96$; p=0.046). Patients with large focal lesions (${\geq}5cm$) had different ALBI scores ($-1.02{\pm}0.63$ vs. $-1.72{\pm}0.59$; p=0.001) serum talin-1 ($9.72{\pm}13.81$ vs. $28.6{\pm}38.89ng/ml$; p=0.007) and fibrosis index scores ($0.85{\pm}0.99$ vs. $4.20{\pm}4.85$; p=0.026). No statistical differences were noted between patients with and without portal vein thrombosis. For detection of HCC, serum talin-1 had 97.7% sensitivity and 100% specificity with a 17.2 ng/ml cutoff. AFP at a 13.7 ng/ml cutoff had 72.1% sensitivity and 6.3.6% specificity. The cutoff for the $fibro-{\alpha}$ score was 1.61 with 81.4% sensitivity and 77.3% specificity. Serum talin-1 (odds=1.08; C.I=1.016-1.150; p=0.014), fibrosis index score (odds=2.35; C.I=1.055-5.217; p=0.037) and the ALBI score (odds=6.9; C.I=1.924-24.708; p=0.003) were predictors of large focal lesions. Conclusions: Serum talin-1, AST/ALT ratio, $fibro-{\alpha}$ score are useful for the assessment of HCC patients.


  1. Bate N, Gingras AR, Bachir A, et al (2012). Talin contains a C-terminal calpain2 cleavage site important in focal adhesion dynamics. PLoS One, 7, 34461.
  2. Bostanci O, Kemik O, Kemik A, et al (2014). A novel screening test for colon cancer: Talin-1. Eur Rev Med Pharmacol Sci, 18, 2533-7.
  3. Bota S, Sirli R, Sporea I, et al (2011). A new scoring system for prediction of fibrosis in chronic hepatitis C. Hepat Mon, 11, 548-55.
  4. Bravi F, Bosetti C, Tavani A, et al (2013). Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol, 11, 1413-21.
  5. Bruix J, Gores GJ, Mazzaferro V (2014). Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 63, 844-55.
  6. Byam J, Renz J, Millis JM (2013). Liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr, 2, 22-30.
  7. Chan AW, Kumada T, Toyoda H, et al (2016). Integration of albumin-bilirubin (ALBI) score into Barcelona clinic liver cancer (BCLC) system for hepatocellular carcinoma. J Gastroenterol Hepatol.
  8. Chung HA, Kim JH, Hwang Y, et al (2016). Noninvasive fibrosis marker can predict recurrence of hepatocellular carcinoma after radiofrequency ablation. Saudi J Gastroenterol, 22, 57-63.
  9. Cross TJ, Rizzi P, Berry PA, et al (2009). King's Score: an accurate marker of cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol, 21, 730-8.
  10. Desiniotis A, Kyprianou N (2011). Significance of talin in cancer progression and metastasis. Int Rev Cell Mol Biol, 289, 117-47.
  11. European Association for the Study of the L, European Organisation for R, Treatment of C EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 56, 908-43.
  12. Fang KP, Zhang JL, Ren YH, et al (2014). Talin-1 correlates with reduced invasion and migration in human hepatocellular carcinoma cells. Asian Pac J Cancer Prev, 15, 2655-61.
  13. Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55.
  14. Hann HW, Wan S, Lai Y, et al (2015). Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol, 30, 131-8.
  15. Hiraoka A, Kumada T, Michitaka K, et al (2015). Usefulness of albumin-bilirubin (ALBI) grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol.
  16. Islam S, Antonsson L, Westin J, et al (2005). Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol, 40, 867-72.
  17. Ito T, Kumada T, Toyoda H, et al (2015a). FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function. J Cancer Res Clin Oncol, 141, 1311-9.
  18. Ito T, Kumada T, Toyoda H, et al (2015b). Utility of the FIB-4 Index for hepatocarcinogenesis in hepatitis C virus carriers with normal alanine aminotransferase levels. J Viral Hepat, 22, 777-83.
  19. Johnson PJ, Berhane S, Kagebayashi C, et al (2015). Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol, 33, 550-8.
  20. Kim TK, Lee E, Jang HJ (2015). Imaging findings of mimickers of hepatocellular carcinoma. Clin Mol Hepatol, 21, 326-43.
  21. Kirstein MM, Vogel A (2014). The pathogenesis of hepatocellular carcinoma. Dig Dis, 32, 545-53.
  22. Lai MT, Hua CH, Tsai MH, et al (2011). Talin-1 overexpression defines high risk for aggressive oral squamous cell carcinoma and promotes cancer metastasis. J Pathol, 224, 367-76.
  23. Lok AS, Ghany MG, Goodman ZD, et al (2005). Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatol, 42, 282-92.
  24. Ogasawara S, Chiba T, Ooka Y, et al (2015). Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. Invest New Drugs.
  25. Ohta T, Sakaguchi K, Fujiwara A, et al (2006). Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama, 60, 77-84.
  26. Omran MM, Farid K, Emran TM, et al (2011). Fibro-${\alpha}$ score as a simple and useful non-invasive test for predicting significant liver fibrosis in chronic hepatitis C patients. Arab J Gastroenterol, 12, 74-9.
  27. Pang Q, Bi JB, Xu XS, et al (2015). King's score as a novel prognostic model for patients with hepatitis B-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol, 27, 1337-46.
  28. Park LS, Tate JP, Justice AC, et al (2011). FIB-4 index is associated with hepatocellular carcinoma risk in HIVinfected patients. Cancer Epidemiol Biomarkers Prev, 20, 2512-7.
  29. Pinato DJ, Karamanakos G, Ishizuka M, et al (2015). The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application. Liver Int, 35, 2458-65.
  30. Sakamoto S, McCann RO, Dhir R, et al (2010). Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res, 70, 1885-95.
  31. Schuppan D, Afdhal NH (2008). Liver cirrhosis. Lancet, 371, 838-51.
  32. Shaheen AA, Myers RP (2007). Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatol, 46, 912-21.
  33. Shen SL, Fu SJ, Chen B, et al (2014). Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection. Ann Surg Oncol, 21, 3802-9.
  34. Song PP, Xia JF, Inagaki Y, et al (2016). Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol, 22, 262-74.
  35. Suh B, Park S, Shin DW, et al (2015). High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. Hepatol, 61, 1261-8.
  36. Vallet-Pichard A, Mallet V, Nalpas B, et al (2007). FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatol, 46, 32-6.
  37. Waller LP, Deshpande V, Pyrsopoulos N (2015). Hepatocellular carcinoma: A comprehensive review. World J Hepatol, 7, 2648-63.
  38. Youns MM, Abdel Wahab AH, Hassan ZA, et al (2013). Serum talin-1 is a potential novel biomarker for diagnosis of hepatocellular carcinoma in Egyptian patients. Asian Pac J Cancer Prev, 14, 3819-23.
  39. Zhang JL, Qian YB, Zhu LX, et al (2011). Talin1, a valuable marker for diagnosis and prognostic assessment of human hepatocelluar carcinomas. Asian Pac J Cancer Prev, 12, 3265-9.